Acute myeloid leukemia (AML), is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also start in other types of blood-forming cells. In AML, there is a fast production of the abnormal WBCs that get accumulated in the bone marrow, and affect the production of normal blood cells.
The major factors that drive the market growth include advantages of biopharmaceuticals over conventional medicines, rise in geriatric population, unhealthy lifestyle, strong biopharmaceutical pipeline, and development of combination therapies that can treat diseases that were previously untreated. However, high cost of the therapeutic process, and its safety concerns, is expected to hinder the growth of the market. Moreover, ongoing researches have led to discovery of more efficient therapies for cancer treatment, which pose attractive opportunities for the key market players.
The global acute myeloid leukemia therapeutics market is segmented on the basis of treatment type and geography. According to treatment type, the market is divided into cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key players profiled in the report include Eli Lilly and Company, Genzyme Corporation, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Celegene Corporation, Cephalon, Inc., and Eisai Inc.
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market by type elucidates the regional trends.
- Key players and their strategies are analyzed to understand the competitive outlook of the market.
Acute Myeloid Leukemia Therapeutics Market Key Segments:
By Treatment Type
- Anthracycline Drugs
- Alkylating Agents
- Tyrosine Kinase Inhibitors
- Dasatinib (Sprycel)
- Imatinib (Gleevec)
- Hormonal Therapy
- North America
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- Rest of LAMEA